Today Audentes Therapeutics Inc (NASDAQ:BOLD) Reported Increase in Shorted Shares

April 19, 2018 - By Michael Collier

The stock of Audentes Therapeutics Inc (NASDAQ:BOLD) registered an increase of 17.61% in short interest. BOLD’s total short interest was 2.24 million shares in April as published by FINRA. Its up 17.61% from 1.90M shares, reported previously. With 413,900 shares average volume, it will take short sellers 5 days to cover their BOLD’s short positions. The short interest to Audentes Therapeutics Inc’s float is 13.05%.

The stock decreased 1.41% or $0.55 during the last trading session, reaching $38.54. About 111,785 shares traded. Audentes Therapeutics, Inc. (NASDAQ:BOLD) has risen 72.67% since April 19, 2017 and is uptrending. It has outperformed by 61.12% the S&P500.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company has market cap of $1.41 billion. The firm is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It currently has negative earnings. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.